At this market cap, to have a drug that has been objectively assessed via biomarkers (albeit not statistically significant yet) to be a disease modifying drug for a neurological disorder with no current treatment is as good as it gets imo. The 201 readout next year is going to be a watershed moment for MSA sufferers I think.
This can be a US500 M net annual sales drug within 5 years if the science continues to play out....
At this market cap, to have a drug that has been objectively...
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $32 | 10.62K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 6683279 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 130404453 | 29 |
View Market Depth
| Last trade - 09.59am 27/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |